Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab (M281) in healthy volunteers
NCT02828046Phase 1Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in myasthenia gravis (MG), warm autoimmune hemolytic anemia (wAIHA) and hemolytic disease of the fetus and newborn (HDFN) comparing Placebo with M281 (2 arms). Primary endpoint: Counts and Percentages of adverse events by treatment group. Started May 2016; status: completed.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)warm autoimmune hemolytic anemia (wAIHA)hemolytic disease of the fetus and newborn (HDFN)
Beyond the preview
Go deeper on NCT02828046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828046.